NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Descending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
35356-0250-00 | 35356-0250 | Estrogens, Conjugated, conjugated estrogens | Premarin | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | March 22, 2012 | Dec. 31, 2014 | No Longer Used | |
00046-1103-81 | 00046-1103 | Estrogens, Conjugated | Premarin | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 1, 2006 | In Use | ||
55154-0219-08 | 55154-0219 | Estrogens, Conjugated | Premarin | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 1, 2006 | In Use | ||
69189-1105-01 | 69189-1105 | Estrogens, Conjugated | Premarin | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2015 | May 24, 2017 | No Longer Used | |
45629-0089-01 | 45629-0089 | Tivozanib | FOTIVDA | 0.89 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | March 10, 2021 | In Use | |
25021-0801-66 | 25021-0801 | Zoledronic Acid | Zoledronic Acid | 0.8 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Dec. 29, 2014 | In Use | ||
25021-0801-67 | 25021-0801 | Zoledronic Acid | Zoledronic Acid | 0.8 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Sept. 1, 2015 | Oct. 31, 2018 | In Use | |
63629-4129-01 | 63629-4129 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 8, 2010 | In Use | |
63629-4129-02 | 63629-4129 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 8, 2010 | In Use | |
63629-4129-03 | 63629-4129 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 8, 2010 | In Use |
Found 10,000 results in 9 milliseconds — Export these results